Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA
Betsy Goodfellow | September 14, 2023 | News story | Medical Communications |Â Â FDA, Internal Medicine, Madrigal Pharma, nash, resmetiromÂ
Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for resmetirom for the treatment of adult patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis.
The FDA has granted the drug Priority Review and designated a Prescription Drug User Fee Act date for 14 March 2024 – this is the target date by which the FDA should have completed its review process.
The drug is a once-daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target the underlying causes of NASH in the liver. The development programme includes 18 clinical studies to support the NDA, 12 of which are phase 1, two phase 2 and four phase 3.
Bill Sibold, Madrigal’s CEO commented: “NASH with liver fibrosis represents a significant unmet need in healthcare today: the disease has a serious impact on patients and, without treatment, it can lead to increased risk of cirrhosis, liver failure, liver cancer and premature mortality. Resmetirom is a liver-directed therapy that has demonstrated the potential to treat the liver fibrosis that is associated with these negative outcomes, while resolving the underlying steatohepatitis that drives the disease. The FDA’s acceptance of our NDA with priority review is an important step forward as we pursue our goal of delivering the first approved treatment to patients with NASH with liver fibrosis.”
Betsy Goodfellow
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …
